Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice

Journal of Virology

Volumn 78, Issue 14, 2004, Pages 7610-7618

  Guebre Xabier, Mimi ^a   Hammond, Scott A ^a   Ellingsworth, Larry R ^a   Glenn, Gregory M ^a  

^a IOMAI Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI ENTEROTOXIN; ESCHERICHIA COLI ENTEROTOXIN IMMUNOSTIMULATING AGENT; HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOGLOBULIN G; IMMUNOSTIMULATING AGENT; INFLUENZA VACCINE; MUCOSA ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

AGING; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; DRUG EFFECT; DRUG SAFETY; ELDERLY CARE; ESCHERICHIA COLI; FEMALE; IMMUNE RESPONSE; IMMUNOPOTENTIATION; IMMUNOSTIMULATION; INFLUENZA VIRUS; MOUSE; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AGING; ANIMALS; ANTIBODIES, VIRAL; BACTERIAL TOXINS; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; IMMUNITY, MUCOSAL; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION;

EID: 3142769174     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.14.7610-7618.2004     Document Type: Article

References (44)

1. Barker, W. H., and J. P. Mullooly. 1980. Impact of epidemic type A influenza in a defined adult population. Am. J. Epidemiol. 112:798-811.
2. Berry, L. J., D. K. Hickey, K. A. Skelding, S. Bao, A. M. Rendina, P. M. Hansbro, C. M. Gockel, and K. W. Beagley. 2004. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect. Immun. 72:1019-1028.
3. Cella, M., A. Engering, V. Pinet, J. Pieters, and A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782-787.
4. Crocetti, E., S. Arniani, F. Bordoni, G. Maciocco, M. Zappa, and E. Buiatti. 2001. Effectiveness of influenza vaccination in the elderly in a community in Italy. Eur. J. Epidemiol. 17:163-168.
5. Cumberbatch, M., M. Bhushan, R. J. Dearman, I. Kimber, and C. E. Griffiths. 2003. IL-1β-induced Langerhans' cell migration and TNF-α production in human skin: regulation by lactoferrin. Clin. Exp. Immunol. 132:352-359.
6. Cumberbatch, M., R. J. Dearman, R. W. Groves, C. Antonopoulos, and I. Kimber. 2002. Differential regulation of epidermal Langerhans cell migration by interleukins (IL)-1α and IL-1β during irritant- and allergen-induced cutaneous immune responses. Toxicol. Appl. Pharmacol. 182:126-135.
7. Cumberbatch, M., R. J. Dearman, and I. Kimber. 2002. Influence of ageing on Langerhans cell migration in mice: identification of a putative deficiency of epidermal interleukin-1β. Immunology 105:466-477.
8. D'Alessio, D. J., P. M. Cox, Jr., and E. C. Dick. 1969. Failure of inactivated influenza vaccine to protect an aged population. JAMA 210:485-489.
9. Davies, J. R., and E. A. Grilli. 1989. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol. Infect. 102:325-333.
10. de Bruijn, I. A., E. J. Remarque, C. M. Jol-van der Zijde, M. J. van Tol, R. G. Westendorp, and D. L. Knook. 1999. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J. Infect. Dis. 179:31-36.
11. DeFranco, A. L. 1999. B-lymphocyte activation, p. 225-261. In W. E. Paul (ed.), Fundamental immunology, 4th ed. Lippincott-Raven, Philadelphia, Pa.
12. European Agency for the Evaluation of Medicinal Products. 1997. CPMP note for guidance on harmonisation of requirements for influenza vaccines. Human Medicines Evaluation Unit, European Agency for the Evaluation of Medicinal Products, London, England.
13. Feery, B. J., M. G. Evered, and E. I. Morrison. 1979. Different protection rates in various groups of volunteers given subunit influenza virus vaccine in 1976. J. Infect. Dis. 139:237-241.
14. Fukuda, K., R. A. Levandowski, C. B. Bridges, and N. J. Cox. 2004. Inactivated influenza vaccines, p. 339-370. In S. A. Plotkin and W. A. Orenstein (ed.), Vaccines, 4th ed. Elsevier, Inc., Philadelphia, Pa.
15. Gasparinf, R., T. Pozzi, E. Montomoli, E. Fragapane, F. Senatore, M. Minutello, and A. Podda. 2001. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol. 17:135-140.
16. Geissmann, F., M. C. Dieu-Nosjean, C. Dezutter, J. Valladeau, S. Kayal, M. Leborgne, N. Brousse, S. Saeland, and J. Davoust. 2002. Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J. Exp. Med. 196:417-430.
17. Glenn, G. M., R. T. Kenney, S. A. Hammond, and L. R. Ellingsworth. 2003. Transcutaneous immunization and immunostimulant strategies. Immunol. Allergy Clin. N. Am. 23:787-813.
18. Glenn, G. M., T. Scharton-Kersten, R. Vassell, C. P. Mallett, T. L. Hale, and C. R. Alving. 1998. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161:3211-3214.
19. Glenn, G. M., T. Scharton-Kersten, R. Vassell, G. R. Matyas, and C. R. Alving. 1999. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. 67:1100-1106.
20. Glenn, G. M., D. N. Taylor, X. Li, S. Frankel, A. Montemarano, and C. R. Alving. 2000. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6:1403-1406.
21. Gockel, C. M., S. Bao, and K. W. Beagley. 2000. Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. Mol. Immunol. 37:537-544.
22. Godefroy, S., L. Goestch, H. Plotnicky-Gilquin, T. N. Nguyen, D. Schmitt, M. J. Staquet, and N. Corvaia. 2003. Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against respiratory syncytial virus (RSV). Vaccine 21:1665-1671.
23. Govaert, T. M., M. J. Sprenger, G. J. Dinant, K. Aretz, N. Masurel, and J. A. Knottnerus. 1994. Immune response to influenza vaccination of elderly people: a randomized double-blind placebo-controlled trial. Vaccine 12:1185-1189.
24. Gross, P. A., A. W. Hermogenes, H. S. Sacks, J. Lau, and R. A. Levandowski. 1995. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann. Intern. Med. 123:518-527.
25. Guebre-Xabier, M., S. A. Hammond, D. E. Epperson, J. Yu, L. Ellingsworth, and G. M. Glenn. 2003. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J. Virol. 77:5218-5225.
26. Guerena-Burgueno, F., E. R. Hall, D. N. Taylor, F. J. Cassels, D. A. Scott, M. K. Wolf, Z. J. Roberts, G. V. Nesterova, C. R. Alving, and G. M. Glenn. 2002. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 70:1874-1880.
27. Haan, L., W. R. Verweij, M. Holtrop, R. Brands, G. J. van Scharrenburg, A. M. Palache, E. Agsteribbe, and J. Wilschut. 2001. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 19:2898-2907.
28. Halperin, S. A., B. Smith, T. Mabrouk, M. Germain, P. Trepanier, T. Hassell, J. Treanor, R. Gauthier, and E. L. Mills. 2002. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20:1240-1247.
29. Hammond, S. A., M. Guebre-Xabier, J. Yu, and G. M. Glenn. 2001. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. Crit. Rev. Ther. Drug Carrier Syst. 18:503-526.
30. Higgins, D. A., J. R. Carlson, and G. Van Nest. 1996. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 14:478-484.
31. Hirota, Y., M. Kaji, S. Ide, J. Kajiwara, K. Kataoka, S. Goto, and T. Oka. 1997. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine 15:962-967.
32. Michetti, P., C. Kreiss, K. L. Kotloff, N. Porta, J. L. Blanco, D. Bachmann, M. Herranz, P. F. Saldinger, I. Corthesy-Theulaz, G. Losonsky, R. Nichols, J. Simon, M. Stolte, S. Ackerman, T. P. Monath, and A. L. Blum. 1999. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116:804-812.
33. Miller, R. A. 1996. Aging and the immune response, p. 355-392. In E. Schneider and J. Rowe (ed.), Handbook of the biology of aging. Academic Press, San Diego, Calif.
34. Murali-Krishna, K., J. D. Altman, M. Suresh, D. J. Sourdive, A. J. Zajac, J. D. Miller, J. Slansky, and R. Ahmed. 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8:177-187.
35. Mutsch, M., W. Zhon, P. Rhodes, M. Bopp, R. T. Chen, T. Linder, C. Spyr, and R. Steffen. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350:896-903.
36. Nichol, K. L., J. Nordin, J. Mullooly, R. Lask, K. Fillbrandt, and M. Iwane. 2003. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N. Engl. J. Med. 348:1322-1332.
37. Pittman, P. R., G. Kim-Ahn, D. Y. Pifat, K. Coonan, P. Gibbs, S. Little, J. G. Pace-Templeton, R. Myers, G. W. Parker, and A. M. Friedlander. 2002. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20:1412-1420.
38. Rescigno, M., S. Citterio, C. Thery, M. Rittig, D. Medaglini, G. Pozzi, S. Amigorena, and P. Ricciardi-Castagnoli. 1998. Bacteria-induced neo-biosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells. Proc. Natl. Acad. Sci. USA 95:5229-5234.
39. Scharton-Kersten, T., J. Yu, R. Vassell, D. O'Hagan, C. R. Alving, and G. M. Glenn. 2000. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68:5306-5313.
40. Schuler, G., and R. M. Steinman. 1985. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J. Exp. Med. 161:526-546.
41. Treanor, J. J., H. R. Mattison, G. Dumyati, A. Yinnon, S. Erb, D. O'Brien, R. Dolin, and R. F. Betts. 1992. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann. Intern. Med. 117:625-633.
42. Walker, R. I. 1994. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 12:387-400.
43. Webster, R. G. 2000. Immunity to influenza in the elderly. Vaccine 18:1686-1689.
44. Yu, J., F. Cassels, T. Scharton-Kersten, S. A. Hammond, A. Hartman, E. Angov, B. Corthesy, C. Alving, and G. Glenn. 2002. Transcutaneous immunization using colonization factor and LT induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect. Immun. 70:1056-1068.